Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Parkinson's Disease
NCT02953665Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Apr 2017
- Primary completion
- Aug 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of liraglutide in Parkinson's disease (PD), sponsored by Cedars-Sinai Medical Center. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02953665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953665.